Intech Investment Management LLC Buys 83,105 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Intech Investment Management LLC raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 147.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 139,410 shares of the biopharmaceutical company's stock after acquiring an additional 83,105 shares during the period. Intech Investment Management LLC owned about 0.11% of Halozyme Therapeutics worth $6,665,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in HALO. CBIZ Investment Advisory Services LLC bought a new position in shares of Halozyme Therapeutics during the 4th quarter valued at $29,000. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics in the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC boosted its stake in shares of Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth approximately $69,000. Finally, Parkside Financial Bank & Trust increased its stake in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 322 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the sale, the director now directly owns 33,611 shares in the company, valued at approximately $1,972,629.59. This trade represents a 12.95 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares of the company's stock, valued at approximately $10,765,546.65. The trade was a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 31,697 shares of company stock valued at $1,754,451 in the last 90 days. Corporate insiders own 2.40% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HALO. Wells Fargo & Company cut their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Piper Sandler increased their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Finally, Benchmark restated a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $62.78.

Halozyme Therapeutics Stock Up 1.3 %

HALO stock traded up $0.84 during midday trading on Friday, hitting $65.16. The stock had a trading volume of 4,001,023 shares, compared to its average volume of 1,329,696. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The firm has a market cap of $8.05 billion, a price-to-earnings ratio of 19.00, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The business has a 50-day moving average of $58.20 and a two-hundred day moving average of $54.71. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.